RDHL Projected Dividend Yield

Level 2 Sponsored ADR Par/Redhill Biopharma Ltd, Ramat Gan ( NASDAQ : RDHL )

RedHill Biopharma is a biopharmaceutical company that focuses on commercialization and development of proprietary drugs for gastrointestinal (GI) diseases. The ongoing development programs of Co.'s therapeutic candidates, most in late-stage clinical development, include: RHB-204, which is for the treatment of mycobacterium avium complex disease; RHB-104, which is an investigational drug intended to treat Crohn's disease; RHB-102 (Bekinda®), which is an investigational once-daily bi-modal extended-release oral formulation of ondansetron; and RHB-106, which is an investigational tablet intended for the preparation and cleansing of the GI tract prior to the performance of abdominal procedures.

20 YEAR PERFORMANCE RESULTS